Paper Details

  1. Home
  2. Paper Details

Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran.

Author: GharagozliKurosh, GhorbanieMehdie, HemmatieAbolfazl, KalanieAmir Reza, KalanieHossein

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the efficacy and safety of interferon beta-1a (Avonex) and intravenous immunoglobulin (IVIG) for treating relapsing-remitting multiple sclerosis in Iranian patients. Both treatments effectively reduced relapse rate, but IVIG demonstrated a slightly better safety profile and led to a greater decrease in disability score.
Paper Details　
Original Abstract of the Article :
The aim of the study was to evaluate the efficacy and safety of interferon beta-1a (Avonex) and intravenous immunoglobulin (IVIG) in clinical practice for the treatment of relapsing-remitting multiple sclerosis. Avonex is the most common disease-modifying therapy used in Iran due to its ease of admi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000082036

データ提供：米国国立医学図書館（NLM）

Interferon Beta-1a and IVIG: A Comparison in Treating Multiple Sclerosis

The vast and often challenging desert of multiple sclerosis (MS) research continues to seek effective treatments for this complex and debilitating condition. This study, like a caravan traversing a challenging terrain, compared the efficacy and safety of interferon beta-1a (Avonex) and intravenous immunoglobulin (IVIG) in treating relapsing-remitting MS in Iranian patients. The researchers aimed to assess the effectiveness of these treatments in reducing relapse rates and managing disability progression.

A Promising Outlook: Both Treatments Show Efficacy in MS Management

The study found that both interferon beta-1a and IVIG were effective in reducing annual relapse rates, with IVIG demonstrating a slightly greater reduction compared to interferon beta-1a. IVIG also showed a significant improvement in the Expanded Disability Status Scale (EDSS) score compared to interferon beta-1a. While both treatments were well-tolerated, IVIG exhibited a more favorable safety profile.

A Glimmer of Hope in the Desert of MS Research

This study offers a glimmer of hope in the desert of MS research, suggesting that both interferon beta-1a and IVIG can be effective treatments for relapsing-remitting MS. The findings highlight the importance of considering individual patient needs and preferences when choosing a treatment option. While the study's limited sample size and duration warrant further research, the results provide valuable insights into the potential therapeutic benefits of these treatments.

Dr.Camel's Conclusion

This study, like a caravan discovering a hidden oasis, offers valuable insights into the treatment of multiple sclerosis. The findings suggest that both interferon beta-1a and IVIG can be effective in reducing relapse rates and managing disability progression. While further research is needed, this study provides a promising glimpse into the future of MS treatment.

Date :
  1. Date Completed 2005-03-07
  2. Date Revised 2007-11-15
Further Info :

Pubmed ID

15539773

DOI: Digital Object Identifier

10.1159/000082036

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.